3 reasons why Healthscope Ltd is my top pick for November

Healthscope Ltd (ASX: HSO)  is the second-largest provider of private hospital services in Australia and a leading provider of pathology services in New Zealand, Malaysia, and Singapore.

Its share price has been troubled over the last year following announcements that the company was experiencing weaker-than-expected sales volumes which would translate to flat earnings growth for the year when annualised.

In addition to this, the company announced the sale of its medical centres for $55m, a massive discount to book value which resulted in a non-cash impairment loss of $54.7m in relation to the sale.

Despite its challenges, Healthscope was my top pick for November for the following reasons:

  • Great long term prospects. There is likely to be ongoing strong demand for Healthscope’s services due to an ageing population and the government’s support for private health operators. Healthscope’s position as the second largest private operator makes it well placed to take advantage of this long term trend.
  • Valuation. In my view, the market sell off of Healthscope shares over the last year has made its valuation attractive. Its price to earnings ratio of 23 is much lower than its competitor Ramsay Health Care Limited (ASX: RHC) which has a PE ratio of 32. It is important to note however, that whilst Healthscope is only focused on the Australian market, Ramsay has significant international operations.
  • Strong balance sheet. Healthscope raised capital and paid a significant portion of its debt resulting in a healthy and sustainable financial position. The company earns stable cash flow from the hospital business and whilst capital expenditure is forecast to be high over the coming years because of the brownfield hospital expansion program, cash flows from operations and existing debt facilities should be sufficient to cover this.

Overall, at a time where value is difficult to find, Healthscope is a business I would consider for my portfolio.

If Healthscope is not for you, you can try our number 1 dividend pick to buy now….

OUR #1 dividend pick to grow your wealth over the new financial year is revealed for FREE here!

Financial year 2018 is here and The Motley Fool’s dividend detective Andrew Page has revealed his must buy dividend share to grow your wealth in 2018.

You might not know this market leader, but it’s making waves in Asia and already boasts a term-deposit-crushing dividend above 4%. A debt free balance sheet and dominant market position at home and abroad mean this company offers investors income and some real-deal growth potential...

Simply click here to grab your FREE copy of this up-to-the-minute research report on this rising star right now.

Motley Fool contributor Kevin Gandiya has no position in any of the stocks mentioned.

You can follow Kevin on Twitter @KevinGandiya

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.